MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Panels are designed for use in determining quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-negative bacilli. The MicroScan® rapID/S play® 40 growing actions and faculture and on the WalkAway SV System or equivalent (upgraded WalkAway® 40 or WalkAway® 96 instruments).

The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test that have The allinited in Mueller-Hinton Broth to concentrations bridging the range of clinical interest and are presented in micro-titer wells in dried form. rapID/S plus™ panels are inoculated and rehydrated with a standardized suspension of the organism and incubated at 35℃ in the WalkAway® S/ System or equivalent standardized suspension of the organism and securition (MIC) for the test organism is determined by the lowest antimicrobial concentration showing inhibition of growth.

AI/ML Overview

The provided text describes the 510(k) summary for the MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Panels with Gentamicin. Here's a breakdown of the requested information:

1. Table of Acceptance Criteria and Reported Device Performance

The text primarily focuses on the "Essential Agreement" metric, which is a common performance criterion for antimicrobial susceptibility devices. While specific numerical acceptance criteria (e.g., "should be > X%") are not explicitly stated, the reported performance is given.

Metric	Acceptance Criteria (Implied)	Reported Device Performance
Overall Essential Agreement (compared to NCCLS frozen Reference Panel)	Undefined but implied to be high for acceptance.	Greater than 96% for Gentamicin
Reproducibility for Gentamicin (with Turbidity inoculum preparation and WalkAway® SI System)	Acceptable	Acceptable
Quality Control testing for Gentamicin	Acceptable	Acceptable

2. Sample Size Used for the Test Set and Data Provenance

The text states: "The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains." However, no specific sample size (number of isolates/strains) is provided for the test set.

The data provenance is not explicitly stated in terms of country of origin. The study appears to be retrospective (using "fresh and stock isolates") rather than prospective, as it's an evaluation of an existing methodology against a reference.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Experts

This information is not provided in the document. The ground truth for the test set was established against an "NCCLS frozen Reference Panel" and "Expected Results" for Challenge strains, but the process of how these reference results were generated or by whom is not detailed.

4. Adjudication Method for the Test Set

This information is not provided in the document. The comparison was made against a "NCCLS frozen Reference Panel" and "Expected Results," implying a direct comparison without a separate adjudication process among multiple readers/evaluators of the device's results.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No MRMC comparative effectiveness study is mentioned. The study described is a standalone performance evaluation against a reference standard. The device determines antimicrobial susceptibility automatically, so the concept of "human readers improve with AI vs without AI assistance" does not directly apply here.

6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study

Yes, a standalone study was performed. The described evaluation assesses the performance of the MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Panel (the device itself) in determining antimicrobial susceptibility. The device interprets the results to determine the Minimum Inhibitory Concentration (MIC) for the test organism without human intervention during the reading process. The text states: "The MIC for the test organism is determined by the lowest antimicrobial concentration showing inhibition of growth."

7. Type of Ground Truth Used

The ground truth used was a reference standard. Specifically:

An NCCLS frozen Reference Panel was used for comparison of the rapID/S plus™ Gram-Negative Panel.
"Expected Results" were used for Challenge strains.

8. Sample Size for the Training Set

This information is not provided in the document. The text describes an evaluation study, but details about the development or training of the device's underlying algorithms (if any complex algorithms are involved beyond direct measurement) are not included.

9. How the Ground Truth for the Training Set Was Established

Since the sample size for the training set is not provided, and the document focuses on the evaluation, how the ground truth for any potential training set was established is not detailed.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. In the center of the circle is an abstract symbol that resembles an eagle or bird in flight.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

AUG 3 0 2004

Mr. Robert Eusebio Manager Regulatory Affairs Dade MicroScan, Inc. 1584 Enterprise Boulevard West Sacramento, CA 95691

K020185 Re: Trade/Device Name: MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Panels with Gentamicin (0.12-32 µg/ml) Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices Regulatory Class: Class II Product Code: LON Dated: July 30, 2004 Received: August 3, 2004

Dear Mr. Eusebio:

This letter corrects our substantially equivalent letter of February 6, 2002, regarding the trade name which was changed to MicroScan® Synergies Plus to better reflect the intended use of the device.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent [(for the indications for use stated in the enclosure)] to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-3084. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at their toll free number (800) 638-2041 or at (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Leddiu. Poole for

Sally A. Hojvat, M.Sc., F Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use Statement

510(k) Number (if known): K020185

MicroScan® Synergies plus™ MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Device Name: Panels with Gentamicin (0.12 - 32 µg/ml)

Indiaations EarwaikAway® 96) according to the Package Insert.

This particular submission is for the antimicrobial Gentamicin on the Synergies plus™ Gram-Negative MIC/Combo Panels.

The Gram-Negative organisms which may be used for Gentamicin susceptibility testing in this panel are:

Citrobacter amalonaticus Citrobacter koseri (diversus) Citrobacter freundii Citrobacter spp Escherichia coli Enterobacter aerogenes Enterobacter agglomerans Enterobacter cloacae Enterobacter sakazakii Enterobacter spp Klebsiella oxytoca Klebsiella ozaenae

Klebsiella pneumoniae Klebsiella rhinoscleromatis Klebsiella spp Proteus mirabilis Proteus vulgaris Proteus spp Pseudomonas aeruginosa Serratia spp Serratia marcescens Shigella flexneri Shigella sonnei Shigella spp Salmonella spp
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Leddlute: Rock
Division Sign-Off

Office of In Vitro Djagnostic Device Evaluation and Safety

510(k)_02018

Page 1 of 1

{3}------------------------------------------------

KO20185

FEB 0 6 2002

510(k) Summary

510(k) Submission Information:

Device Manufacturer:	Dade Behring Inc.
Contact name:	Maureen Mende, Group Manager Regulatory Affairs
Fax:	916-374-3144
Date prepared:	January 17, 2002
Product Name:	Microdilution Minimum Inhibitory Concentration (MIC) Panel
Trade Name:	MicroScan® rapID/S plus™ Gram-Negative MIC/Combo panels
Intended Use:	To determine antimicrobial agent susceptibility
510(k) Notification:	Antimicrobials: Gentamicin
Predicate device:	MicroScan Dried Gram Negative MIC/Combo Panels

510(k) Summary:

The proposed MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Panel demonstrated substantially equivalent performance when compared with an NCCLS frozen Reference Panel, as defined in the FDA Collivatell performation with on Review Criteria for Assessment of Antimicrobial Susceptibility Devices", dated March 8, 2000. The Premarket Notification (510[k]) presents data in support of the MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Panel with Gentamicin.

The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains. The external evaluations were designed to confirm the acceptability of the proposed rapID/S plus™ Cram-Negative Panel by comparing its performance with an NCCLS frozen Reference panel. Challenge strains were compared to Expected Results determined prior to the evaluation. The rapID/S plus™ Gram-Negative were compared to Exposition overall Essential Agreement of greater than 96% for Gentamicin when compared with the frozen Reference panel.

Instrument reproducibility testing demonstrated acceptable reproducibility and precision with Gentamicin with Turbidity inoculum preparation method and the WalkAway® SI System or equivalent (upgraded WalkAway® 40 or WalkAway® 96 instruments).

Quality Control testing demonstrated acceptable results for Gentamicin.

Regulation Number and Section

§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.

(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”